3.00Open3.00Pre Close0 Volume0 Open Interest9.00Strike Price0.00Turnover522.69%IV-56.25%PremiumJul 19, 2024Expiry Date5.16Intrinsic Value100Multiplier13DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6355Delta0.0979Gamma0.67Leverage Ratio-0.0534Theta-0.0024Rho-0.42Eff Leverage0.0028Vega
uniQure NV Stock Discussion
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
uniQure has received the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for its investigational gene therapy, AMT-130, for Huntington’s disease. This designation is based on 24-month interim data from Phase I/II clinical trials released in December 2023 and represents a significant milestone.
AMT-130 is the firs...
No comment yet